Wearable Cardioverter Defibrillators Market Size & Share by Indication (Myocardial Infarction, Congenital Heart Disease, Ventricular Arrhythmias, Peripartum Cardiomyopathy, Tetralogy Of Fallot, Wolff-Parkinson-White Syndrome); Demography (Pediatric, Adults, Geriatric); End-user (Home Care Settings, Hospitals, Cardiology Clinics, Ambulatory Surgical Center) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2024-2036

  • Report ID: 874
  • Published Date: Nov 17, 2023
  • Report Format: PDF, PPT

Global Market Size, Forecast, and Trend Highlights Over 2024-2036

Wearable Cardioverter Defibrillators Market size is poised to reach USD 24 Billion by the end of 2036, growing at a CAGR of 6% during the forecast period, i.e., 2024-2036. In the year 2023, the industry size of wearable cardioverter defibrillators was USD 14 Billion. The reason behind the growth is due to the rising incidence of cardiovascular diseases across the globe. Cardiovascular disease deaths have increased by more than 55% worldwide in the past 30 years.

Diabetes-related high blood sugar levels can harm the nerves that control the heart and blood vessels, resulting in a variety of cardiovascular diseases such as coronary artery disease, which affects the electrical conduction system in the heart, causing ventricular arrhythmias and atrial fibrillation. This increases the demand for common cardiac disease and rhythm monitoring, which is likely to boost market growth. 

The growing technological advancement in cardiology are believed to fuel the market growth. For instance, artificial intelligence (AI) components are already being utilized in radiology and cardiology's backends including wearable cardiac monitoring devices and point-of-care (POC) triage apps that are being utilized with wearables or smartphone-based apps that record ECG to automatically detect arrhythmias and notify patients.

Get more information on this report: Request Free Sample PDF

Wearable Cardioverter Defibrillators Sector: Growth Drivers and Challenges

Growth Drivers

  • Rising Elderly Population – The number of cardiac arrests among the elderly is expected to rise in the coming decades, as men and the elderly are most vulnerable to cardiac arrest. According to the World Health Organization (WHO), the number of people aged 60 and up will double to 2.1 billion worldwide by 2050.
  • Growing Popularity of Minimally Invasive Procedures- The wearable cardioverter-defibrillator (WCD) is a temporary, non-invasive device that is often given to individuals who are at high risk of arrhythmia.
  • Spiking Incidence of Diabetes- Cardiovascular disease is two to four times more common in people with diabetes than in the general population as high blood sugar levels have the potential to harm heart-controlling neurons and blood arteries over time. By 2030, it is expected that the prevalence of type 2 diabetes will rise to over 7070 cases per 100,000 people worldwide.
  • Increasing Launch of New Products by Major Market Players- For instance, in August 2021, Kestra Medical Technologies received approval from the FDA for an Assure wearable cardioverter defibrillator (WCD) system with integrated sensors, a cardiac rhythm monitor, and a miniaturized automated external defibrillator, to assess a patient's cardiac rhythm, and safely provide defibrillation therapy to return a patient's heart to normal to safeguard patients at risk of sudden cardiac death (SCD).
  • Growing Consumption of Alcohol- One of the main causes of cardiac arrest is alcohol consumption, which also weakens the heart and can cause hypertension and cardiomyopathy, a condition that damages the heart muscle. For instance, every year, alcohol use results in over 2 million premature deaths worldwide.


  • Limited Awareness among People in Developing Countries - In developing countries, the knowledge about the cardioverter-defibrillator is still minimal, which may act as a barrier to the development of the wearable cardioverter defibrillators market. Furthermore, in various low-income countries, there are no strict standards and regulations to evaluate the wearable cardioverter defibrillators' safety and quality. The poorly developed standards across multiple nations have further hindered the usage of wearable cardioverter defibrillators.
  • Stringent Government Regulations can Pose Challenge for Manufacturers
  • High Cost of Wearable Cardioverter Defibrillators can Limit the Adoption and Access for Certain Individuals

Wearable Cardioverter Defibrillators Market: Key Insights

Base Year


Forecast Year




Base Year Market Size (2023)

~ USD 14 Billion

Forecast Year Market Size (2036)

~ USD 24 Billion

Regional Scope

  • North America (U.S., and Canada)
  • Latin America (Mexico, Argentina, Rest of Latin America)
  • Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific)
  • Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)
Get more information on this report: Request Free Sample PDF

Wearable Cardioverter Defibrillators Segmentation

Indication (Myocardial Infarction, Congenital Heart Disease, Ventricular Arrhythmias, Peripartum Cardiomyopathy, Tetralogy Of Fallot, Wolff-Parkinson-White Syndrome)

The peripartum cardiomyopathy segment is estimated to hold 40% share of the global wearable cardioverter defibrillators market in the coming years. Pregnancy-associated cardiomyopathy, commonly known as peripartum cardiomyopathy, is a kind of systolic heart failure (HF) with a reduced left ventricular ejection fraction (LVEF) that affects women who are pregnant or in the months following delivery. Moreover, it is an unusual kind of heart failure that usually manifests with decreased ejection fraction (HFrEF) and is a potentially fatal disorder. This is expected to fuel the demand for a wearable cardioverter defibrillator as it can safely record and stop life-threatening arrhythmias, making it useful for illnesses such as peripartum cardiomyopathy.

End-user (Home Care Settings, Hospitals, Cardiology Clinics, Ambulatory Surgical Center)

The home care settings segment is set to garner a notable share. It is the preferred way of treating patients to preserve their independence and remain in the comfort of their surroundings. Moreover, more people nowadays are focusing more on spending on resources for proper care at home. Furthermore, with the advancement in medical technology, physicians can now assist their patients virtually, which has further led to the increasing acceptance of home care settings. The hospital segment has accounted for a significant market share in the past years and is anticipated to play a key role in the growth of the market on account of an increasing number of hospitals providing numerous options for treatment across developing countries.

Demography (Pediatric, Adults, Geriatric)

The adults segment in the wearable cardioverter defibrillators market is anticipated to gain a robust revenue share of 79% by 2036. People with high risk of cardiovascular diseases usually include adults with hypertension, diabetes, obesity, and other diseases which may increase the demand for wearable cardioverter defibrillators as they can be used to monitor cardiovascular conditions.

Our in-depth analysis of the global market includes the following segments:


  • Myocardial Infarction
  • Congenital Heart Disease
  • Ventricular Arrhythmias
  • Peripartum Cardiomyopathy
  • Tetralogy Of Fallot
  • Wolff-Parkinson-White Syndrome


  • Pediatric
  • Adults
  • Geriatric


  • Home Care Settings
  • Hospitals
  • Cardiology Clinics
  • Ambulatory Surgical Center

Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.

Customize this Report

Wearable Cardioverter Defibrillators Industry - Regional Synopsis

North American Market Forecast

Wearable cardioverter defibrillators market in North America is predicted to account for the largest share of 38% by 2036 impelled by the rising funding in healthcare industry. As a result, more resources are available in the region for research and development of more advanced, and reliable wearable cardioverter defibrillators which would also make these devices cost-effective in the region. In 2021, U.S. health spending climbed by more than 2% to reach over USD 4 trillion.

APAC Market Statistics

The APAC wearable cardioverter defibrillators market is estimated to be the second largest, during the forecast timeframe led by increase in investment towards the medical device sector from government and private entities to maintain the highest quality of services. The Indian government supports the production of medical devices in the country by offering various programs and subsidies under several ministries which has spread the word in the community about the value of leading a healthy lifestyle and the right of everyone to get high-quality medical care. This has led to an increase in demand for various advanced medical devices such as wearable cardioverter defibrillators in the region.

Research Nester
Get more information on this report: Request Free Sample PDF

Companies Dominating the Wearable Cardioverter Defibrillators Landscape

    • ZOLL Medical Corporation
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Element Science Inc.
    • Medtronic plc
    •  Kestra Medical Technologies, Inc.
    •  Abbott
    •  Boston Scientific Corporation
    •  LivaNova plc
    •  Koninklijke Philips N.V.
    •  Nihon Kohden Corporation
    •  General Electric Company.


In The News

  • Medtronic plc announced that it has obtained approval from the U.S. Food and Drug Administration (FDA) for Aurora EV-ICD MRI SureScan (Extravascular Implantable Cardioverter-Defibrillator) and Epsila EV MRI SureScan to offer the advantages of conventional, transvenous ICDs in terms of saving lives by providing anti-tachycardia pacing (ATP), backup (pause-prevention) pacing therapy, and life-saving defibrillation.
  • Abbott received approval from the U.S. Food and Drug Administration (FDA) for Gallant implantable cardioverter defibrillator (ICD) and cardiac resynchronization therapy defibrillator (CRT-D) devices with Bluetooth technology and a new patient smartphone app for better remote monitoring for patients with cardiac rhythm abnormalities.

Author Credits:  Radhika Gupta, Shivam Bhutani

  • Report ID: 874
  • Published Date: Nov 17, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Rising incidence of heart attacks across the globe and the growing technological advancement in cardiology are the major factors driving the growth of the market.

The market size of Wearable Cardioverter Defibrillators is anticipated to attain a CAGR of 6% over the forecast period, i.e., 2024 – 2036.

The major players in the market are ZOLL Medical Corporation, Element Science Inc., Medtronic plc, Kestra Medical Technologies, Inc., Abbott, Boston Scientific Corporation, LivaNova plc, Koninklijke Philips N.V., Nihon Kohden Corporation and General Electric Company., and others.

The peripartum cardiomyopathy segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.

The market in the North American region is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.
Wearable Cardioverter Defibrillators Market Report Scope

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying